Albendazole-praziquantel interaction in healthy volunteers: kinetic disposition, metabolism and enantioselectivity
about
A research agenda for helminth diseases of humans: intervention for control and eliminationPharmacokinetic Study of Praziquantel Enantiomers and Its Main Metabolite R-trans-4-OH-PZQ in Plasma, Blood and Dried Blood Spots in Opisthorchis viverrini-Infected PatientsSafety of the combined use of praziquantel and albendazole in the treatment of human hydatid disease.Activity of praziquantel enantiomers and main metabolites against Schistosoma mansoni.Medical management of neurocysticercosis.Pharmacokinetics of combined treatment with praziquantel and albendazole in neurocysticercosis.Diagnosis and treatment of neurocysticercosis.Two cases of femoral hydatidosis secondary to canine tapeworm treated by albendazole and prosthetic reconstruction.P-glycoproteins and other multidrug resistance transporters in the pharmacology of anthelmintics: Prospects for reversing transport-dependent anthelmintic resistance.Pharmacokinetic variability of anthelmintics: implications for the treatment of neurocysticercosis.Routine drug and food interactions during antihelminthic treatment of neurocysticercosis: a reason for the variable efficacy of albendazole and praziquantel?A review of pharmacokinetic drug-drug interactions with the anthelmintic medications albendazole and mebendazole.Praziquantel for Schistosomiasis: Single-Drug Metabolism Revisited, Mode of Action, and Resistance.Drug-drug interactions--bridging the gulf between the bench and the bedside?
P2860
Q21562256-EBBD9210-F78B-46EF-AE56-96CE2672D986Q28551880-3886ED42-9B53-4C28-9844-31AC1D058A91Q33588473-259AF47F-66DE-4749-9BBA-2E71F104AF13Q34057535-FC688168-BD2C-4BD9-83FE-224C817D5134Q34074147-E323CE08-D4E2-465A-9307-850C80D6DB8CQ35120602-2A172CE9-5869-44CF-B558-CC4B7BC1F9A8Q35953198-77F27F9D-E21C-467C-B97C-3BCD77608A98Q36894023-8C35A5DF-BA26-4B6A-B4F4-0CE09BCE73AAQ37390601-50A9B365-2144-4BAD-9756-539101114674Q37964749-64405E32-E6CD-4EF2-9E90-C1E0C6392AD5Q38180096-ECAAEDB2-5CA2-49F0-A3D4-3FE118DF79F7Q38359488-8D0E3971-0EFE-4F46-A592-3FFA75145722Q39164325-4F2A0872-9A6A-4BDA-986F-D6826E13ED0AQ42720500-F6801ADE-FC52-4641-8300-02598467BC34
P2860
Albendazole-praziquantel interaction in healthy volunteers: kinetic disposition, metabolism and enantioselectivity
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Albendazole-praziquantel inter ...... abolism and enantioselectivity
@ast
Albendazole-praziquantel inter ...... abolism and enantioselectivity
@en
Albendazole-praziquantel inter ...... abolism and enantioselectivity
@nl
type
label
Albendazole-praziquantel inter ...... abolism and enantioselectivity
@ast
Albendazole-praziquantel inter ...... abolism and enantioselectivity
@en
Albendazole-praziquantel inter ...... abolism and enantioselectivity
@nl
prefLabel
Albendazole-praziquantel inter ...... abolism and enantioselectivity
@ast
Albendazole-praziquantel inter ...... abolism and enantioselectivity
@en
Albendazole-praziquantel inter ...... abolism and enantioselectivity
@nl
P2093
P2860
P1476
Albendazole-praziquantel inter ...... abolism and enantioselectivity
@en
P2093
Bruno José Dumêt Fernandes
Eduardo Barbosa Coelho
Hector Hugo Garcia
Maria Augusta Drago Ferreira
Osvaldo Massaiti Takayanagui
Renata Monteiro Lima
Teresa Maria de Jesus Ponte Carvalho
P2860
P304
P356
10.1111/J.1365-2125.2010.03874.X
P407
P577
2011-04-01T00:00:00Z